Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

.3 percent). However, somnolence, sedation and fatigue typically occurred early in the study and most resolved as treatment continued. The incidence of syncopal events was less than 1 percent. In some of the patients who did experience syncope, potential contributing factors were noted (such as dehydration, sudden change in body position, and hot environment). While small changes in average blood pressure and pulse rate occurred, cardiovascular events were uncommon.

For all doses, the mean ADHD-RS-IV total scores and subscale scores showed significant improvement from baseline to endpoint: -18.1 points on the ADHD- RS-IV total; -8.5 points on the ADHD-RS-IV hyperactive/impulsive subscale and -9.5 points on the ADHD-RS-IV inattentive subscale (P <.001).

Similar to the 303 study, the objective of the 305 open-label trial was to assess the long-term safety and efficacy of GXR for the treatment of ADHD in children and adolescents aged 6 to 17 years. During the first month of this study, investigators made weekly adjustments as needed to each participants' once-daily GXR doses from 1 mg to 4 mg for optimal dosing, as defined by 30 percent or more improvement in ADHD-RS-IV total scores.

In this trial, the most commonly reported treatment emergent adverse events greater than 10 percent were somnolence (29.9 percent), headache (19.7 percent), upper respiratory tract infection (15.1 percent), fatigue (12.4 percent) and sedation (11.2 percent). The incidence of syncopal events was less than 2 percent. As in the 303 open-label study, potential contributing factors were noted in some of the patients who did experience syncope. No clinically relevant trends in ECGs, hematologic or laboratory parameters, vital signs, urinalyses, or physical examination were seen.

Interim results from trial 305 showed that for all doses, the mean ADHD- RS-IV total scores showed significant improvement of -21.6 points from baseline to endpoint (P <.001).

About Gua
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... 10, 2014  Breg, Inc., a premier provider ... the FreeRunner™ knee brace with new innovations to ... mal-tracking return to active lifestyles.  FreeRunner,s patent-pending design ... providing support when patients need it most, and ... Patellofemoral issues are the most common ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SPRING, Md., Nov. 19, 2010 Xanodyne Pharmaceuticals ... version of the prescription pain medication propoxyphene, has ... at the request of the U.S. Food and ... manufacturers of Xanodyne,s decision and they will be ...
... Inc., (NYSE: HRC ) invites you to ... Piper Jaffray Health Care Conference in New York City ... You are invited to listen to the ... or access it directly at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=HRC&item_id=3494592 . ...
Cached Medicine Technology:Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market 2Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market 3
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a gymnastics ... 12 years of age that offers everything from gymnastics, dance, ... Camps, is now under new ownership. , Kevin Berry comes ... over six years at The Little Gym of Bellaire in ... has over ten years of experience working with children, including ...
(Date:7/13/2014)... 2014 Max International has ... will be the featured guest at its Charity Exhibition ... Rico. Attendees will learn about Max’s health products ... exhibition basketball games and perform in a 3 point ... health- and energy-boosting supplements , has recently announced former ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Ann Arbor, MI (PRWEB) July 13, 2014 ... online learning program he has just launched at http://www.HealthYourself101.com ... management of visceral obesity. , Power has set out ... and its ill effects that’s actually – dare we say ... , “The program,” says Power, “aims to engage the remote ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... to treat injury, stroke and even Alzheimer,s, experts say , , ... study involving mice suggests the brain,s own stem cells may ... These neural stem cells work by protecting existing cells and ... the University of California, Irvine, were able to bring the ...
... As the seventh leading cause of cancer death worldwide, ... ethnic group and gender. Esophageal cancer is thought to ... interact with the host genome. Researchers have long been ... been conducted on gene-environment interaction and gene polymorphisms for ...
... remove part or all of the colon (colectomy) for people ... researchers in a study published on bmj.com today. ... of the intestine and includes ulcerative colitis and Crohns disease. ... are affected and many people will require colectomy at some ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), ... of a Phase 2a clinical trial evaluating,MAP0005 ... chronic obstructive,pulmonary disease (COPD). MAP0005 is ... long-acting,beta2-agonist delivered to the respiratory tract using ...
... BPUR ) announced today that the trading symbol for ... BPUR at the open of the market on,Wednesday, October ... revert to the following ticker symbols: BPREW reverting to ... Biopure Corporation Biopure Corporation develops, manufactures and ...
... HRAL) announced today that it has formed an alliance ... Stores (NYSE: WMT ) to help,conquer hearing loss ... Starting November 15, 2007, HearAtLast customers will receive a,$100.00 ... with,their American Express card. The promotion is scheduled to ...
Cached Medicine News:Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4
... 1064 DW with the capability of emission at ... increased coagulative and ablative capacities.Smart 1064 DW is ... different wavelengths: ordinary 1064 nm (with powers selectable ... (with powers among 2 and 25 W). This ...
... CO2 system was expressly designed to obtain ... A special source and an equally special ... create particular high energy impulses with constant ... as 'top-flat shaped') allow storage of enough ...
... the ideal instrument for safe, repeatable tissular ... majority of surface lesions can be treated, ... scar tissue, with a minimum of heat ... elimination of anaesthetics, risks and adverse side ...
... laser system with CW intensities of up ... all therapeutic application in modern and efficient ... in super-pulsed mode, designed for even the ... also capable of supplying soft laser pulses ...
Medicine Products: